ASH 2021: Polatuzumab Vedotin Plus Chemotherapy Beats Standard of Care for Untreated Diffuse Large B-Cell Lymphoma
Safety and toxicity profiles were similar between the two regimens
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.